Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart (Kang Yue Da) in adolescents with seasonal allergic rhinitis
CTR20261869Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Keymed Biosciences. Primary endpoint: Safety endpoints. Started May 2026; status: active.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20261869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261869.